UNSPSC 51411709: Ethaverine hydrochloride

This classification denotes a monoamine oxidase inhibitor and calcium channel blocker with the molecular formula C24H29NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Z6T599E49, chemically known as 6,7-diethoxy-1-(3, 4-diethoxybenzyl)isoquinoline hydrochloride but more generally known as ethaverine hydrochloride, which bears US NIH Compound Identifier 3280. European Medicines Agency schedules Ethaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01996MIG.

UNSPSC 51411709 Ethaverine hydrochloride, a Commodity code, identifies a specific pharmaceutical active ingredient that state and local governments procure primarily through emergency medical services programs and multi-state cooperative purchasing arrangements for inclusion in broader advanced life support medication contracts. The solicitations under this code reflect procurement of medications for emergency response and public health programs, where ethaverine hydrochloride may be bundled with other cardiovascular and emergency-care drugs rather than purchased in isolation.

State and local issuing bodies soliciting under this code include municipal fire and rescue departments, state health agencies, and multi-state cooperative purchasing alliances. The City of Tampa's Fire Rescue Department solicited advanced life support medications through a sealed-bid process in April 2026 (Bid No. 26-P-00188, due April 8, 2026) with an estimated contract value of $40,000 and a one-year initial term plus optional renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities across Minnesota and Oregon, with awarded vendors required to distribute through authorized wholesalers and effective July 1, 2026. The Texas Health and Human Services Commission issued an exploratory Request for Information in April 2026 (HHS0017013, due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs serving state pharmacy benefit plans. Recent activity concentrates in Florida, Minnesota, and Texas, with procurement spanning emergency medical services, multi-jurisdictional cooperative purchasing, and state health administration. Vendors should note that MMCAP's pharmaceutical RFP weighted price competitiveness at 75 percent of evaluation and required compliance with cGMP, DSCSA, FDA requirements, and specific insurance thresholds including $5 million in general liability coverage.